跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ZYNLONTA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ZYNLONTA
Authorized
STANDARD
ZYNLONTA
Swedish Orphan Biovitrum AB (Publ)
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
46fa7753eec46e4b
Company
Swedish Orphan Biovitrum AB (Publ)
Type
Standard
Approval Details
Approval Id
46fa7753eec46e4b
Drug Approval Canada Name
ZYNLONTA
Product Name
ZYNLONTA
Status
Approved
Status Date
2025-03-07
Din
02556138
Drug Class
Human
Dosage Form
Powder For Solution
Route Of Administration
Intravenous
Schedule
Prescription , Schedule D
Ahfs
10:00.00
Atc Original
L01FX22 LONCASTUXIMAB TESIRINE
Atc Name
l 01 fx 22
Aig Number
0166604001
Company Name
Swedish Orphan Biovitrum AB (Publ)
Company Address
Tomtebodav 23a, Stockholm, --, Sweden, 11276
Company Detail Path
/organization/swedish-orphan-biovitrum-ab-publ
Company Information
Pharmaceutical Company Name
Swedish Orphan Biovitrum AB (publ)
Name En
Swedish Orphan Biovitrum AB (publ)
Name Zh
索比制药
Country Name
Sweden
Province Name
stockholm,country_se
City Name
solna,stockholm,country_se
Address
Tomtebodavägen 23A
Website
https://www.sobi.com
Description
International biopharmaceutical company focused on rare diseases in haematology, immunology and specialty care; operates in around 30 countries with headquarters in Stockholm. Listed on Nasdaq Stockholm (SOBI).
Active Ingredients
LONCASTUXIMAB TESIRINE
10 MG / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
46fa7753eec46e4b
Type
Standard
Back to Health Canada Approvals